Sullivan
Microsoft has discontinued support for Internet Explorer. To access the Sullivan website, please install a modern browser like Microsoft Edge or Google Chrome.

Viewpoints

Biotech Focused On Developing Non-Opioid Therapeutics to Alleviate Pain Announced IPO

Sullivan was issuer's counsel for Chromocell Therapeutics Corporation, a clinical-stage biotech company focused on developing and commercializing new, non-opioid therapeutics to alleviate pain, in their $6.6 million initial public offering of common stock.

The Sullivan team was led by David Danovitch, director of the firm’s Corporate Department, with partners Charles E. Chambers Jr., Aaron Schleicher and associate Brian Hurley. Sullivan has developed a strength in working with entrepreneurial biotech and tech companies in the U.S. and in Israel.

David E. Danovitch, Charles E. Chambers Jr. and Brian P. Hurley

Artificial Intelligence Company Advised in Growth Financing

Sullivan represented Impact Analytics Inc. in its $5.5 million growth financing round led by Argentum Capital Partners. The company unites artificial intelligence with human validation that brings machine learning to the forefront of data-driven business decisions.

Lewis N. Segall and Johanna Colpritt

Young businesswoman looking at smartphone in spaceship like corridor

Viewpoints

Viewpoints

Past Events

FINRA’s Small-Cap Sweep: Strategic Steps for Broker-Dealers
When: December 2, 2025
People: David E. Danovitch, Michael T. Dyson, Meghan Rohan, Christopher K. Shields and Erika J. Dennery
FINRA Launches Targeted Review of Small-Cap Foreign Offerings
When: October 24, 2025
People: David E. Danovitch, Michael T. Dyson, Meghan Rohan and Erika J. Dennery
Breaking: FinCEN Removes BOI Reporting Requirements for U.S. Companies and U.S. Persons
When: March 28, 2025
People: William C. Hanson, Natalie S. Lederman, Spencer A. Stone and Ida J. Vanto
SEC Expands Confidential Submission Options for Issuers to Facilitate Capital Raising
When: March 10, 2025
People: Eric Victorson and Ilana Neck Levin
Breaking: Corporate Transparency Act Back in Effect with New Filing Deadline on March 21, 2025
When: February 19, 2025
People: William C. Hanson, Natalie S. Lederman, Spencer A. Stone and Ida J. Vanto
Breaking: Corporate Transparency Act on Hold Again
When: December 27, 2024
People: William C. Hanson, Natalie S. Lederman, Spencer A. Stone and Ida J. Vanto
Breaking: Corporate Transparency Act Reinstated with Short Extension of Some Deadlines
When: December 24, 2024
People: William C. Hanson, Natalie S. Lederman, Spencer A. Stone and Ida J. Vanto
Client Alert Update: How Nationwide CTA Preliminary Injunction Impacts Reporting Obligations
When: December 5, 2024
People: William C. Hanson, Natalie S. Lederman, Spencer A. Stone and Ida J. Vanto
Corporate Transparency Act: Client Alert Update
When: December 3, 2024
People: William C. Hanson, Natalie S. Lederman, Spencer A. Stone and Ida J. Vanto
Corporate Transparency Act: Complying with Beneficial Ownership Rules
When: December 8, 2023
People: William C. Hanson and Ida J. Vanto
Demo Days May Soon Be In the Clear
When: April 27, 2020
People: Scott L. Kaufman
City of Boston’s Small Business Financial Relief Fund
When: April 4, 2020
People: David A. Guadagnoli and Jeffrey B. Morlend
Understanding Liquidation Preferences in Venture Financings
When: January 14, 2020
People: Scott L. Kaufman